J.P. Morgan has moved Sika AG, the Swiss specialty chemicals producer, to a Neutral rating from Underweight and increased its December 2027 price target to CHF165 from CHF140. The broker said it believes the market has already factored in the company’s margin risk and therefore sees less near-term downside to the stock.
As part of the change, J.P. Morgan removed Sika from its Negative Catalyst Watch. The broker noted that both its internal projection and consensus estimates set 2026 EBITDA margins at 19.3% - below Sika’s guidance range of 19.5% to 20% - and interpreted that gap as evidence the market has already priced in a potential margin shortfall.
Valuation assumptions were adjusted alongside the rating change. J.P. Morgan raised the valuation multiple applied to its model to 13 times from 11 times, pointing to what it described as "limited further downside earnings risk." The upgraded price target itself is based on a 12 times EV/EBITDA multiple applied to the broker’s 2027 EBITDA estimate of CHF2.39 billion. The bank noted that this multiple remains below Sika’s long-term average, reflecting "continued earnings disappointment and lack of outperformance versus peers."
At a recent Industrials conference, Sika Chief Financial Officer Adrian Widmer provided additional context on the company’s guidance and the drivers behind it. The company’s top-line guidance calls for 1% to 4% local currency growth and, according to Widmer, that outlook initially assumed only a minimal contribution from pricing.
Widmer said the pricing component is now expected to be higher than originally assumed, although that is likely to be offset by lighter volumes. The guidance also includes an assumed 1.5% contribution from acquisitions. On margins, Widmer warned they could be "skewed towards the bottom end of the guidance or may be below, but if it is below, it will be because of better top-line and so absolute EBITDA will be higher."
J.P. Morgan’s numerical projections are closely aligned with market consensus. The broker’s 2026 EBITDA estimate stands at CHF2.17 billion versus consensus at CHF2.16 billion.
Widmer also reviewed regional performance expectations. He said EMEA and the Americas should see improvement in the second quarter. China, which accounts for 9% of group sales, is expected to show trends similar to the first quarter, with a less negative picture in the second half driven by easier year-on-year comparables; sales in China fell 20% in the first quarter. By contrast, Asia excluding China is projected to remain strong.
Despite the upgrade, J.P. Morgan emphasized execution as an ongoing concern. The broker cautioned that execution has disappointed in recent years and that the company still must deliver on its cost savings plan and provide clearer evidence of outperformance relative to peers. In the bank’s words, it would "remain mindful on execution, which has disappointed in recent years, with the company still needing to deliver on its cost savings plan, as well as more evidence of outperformance versus its peers."
The broker highlighted key risks that could alter its view. Those include macroeconomic developments in Europe, the United States and China, and the potential for volumes or pricing pass-through to come in materially better or worse than expected. These risks remain relevant to both the company’s near-term earnings trajectory and longer-term valuation.
Contextual note - The broker’s move reflects a recalibration of risk and reward: with some downside to earnings already reflected in market prices, J.P. Morgan has raised valuation multiples and its price target while keeping a cautious tone on execution and macro sensitivity.